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SUMMARY 
A female schizophrenic patient who developed Stevens Johnson syndrome following carbamazepine treatment is 
reported. This life threatening condition is discussed in context of other adverse effects of the drug, reportedly found 
to be higher in frequency in the psychiatric population. 
The use of carbamazepine in psychiatry is mostly in 
the prophylaxisof bipolar affective disorder (Greist, 1990) 
but often schizophrenics are benefitted as their excitement 
and aggression responds to it (Luchins, 1984). The milder 
and commonly occurring adverse effects of car-
bamazepine are nausea, dizziness, ataxia, blurring of 
vision and skin rashes, but rarely severe conditions like 
Stevens-Johnson syndrome also occur (Fawcett, 1987). 
This life threatening adverse effect is an acute inflam-
matory polymorphic skin disease; this has multiple other 
causes also and it's etiology is not clear. 
The principal sign of the disease is a symmetrical 
distribution of grouped or isolated crops of violaceous 
papules, macules or nodules of 0.5 to 1 cm with a dome 
shaped surface. The lesions enlarge and become purplish. 
In addition to it, there may be vesicles, bullae pustules, 
urticarial lesions and hemorrhagic sites. A rather charac-
teristic lesion is erythema iris, also described as "bull's 
eye" or "target lesion". These are concentric erythematous 
rings with central clearing. The lesions may be present 
anywhere on the body but extensor surfaces are commonly 
involved. Mucous membrane ulceration is also a common 
finding. 
The disease may occur as a primary skin disorder or as 
a skin manifestation of systemic infections, malignant or 
chronic disease of internal organs or as a reaction to 
ingested drugs like sulphonamides, penicillins, phenytoin 
and phenylbutazone (Rees & Rees, 1984; Fawcett, 1987). 
Carbamazepine, mostly used as an antiepileptic, has also 
been rarely known to cause it. (Fawcett, 1987). The fol-
lowing case report describes a schizophrenic patient who 
developed this condition solely due to carbamazepine. 
CASE REPORT 
Mrs. M.C., a 32 year old female was admitted with a 
three year history of mental illness, characterized by 
abusiveness, aggressiveness, muttering to self, poor per-
sonal care, weight loss, appetite loss and reduction in 
sleep. After a thorough psychiatric evaluation, diagnosis 
of chronic schizophrenia, unspecified subtype was estab-
lished. During her hospitalization, she was treated with 
different neuroleptics, one after another because she did 
not respond well to any of them and was finally treated 
with pimozide. The dose of pimozide was increased from 
2 mg/day to 24 mg/day in a three month period. However, 
impulsivity remained an unresolved problem and car-
bamazepine 200 mg twice daily was added. On the 17th 
day after starting carbamazepine therapy, she developed 
fever, headache and myalgia; however no medicines for 
pyrexia were given. In the next 24 hours, she developed 
erythematous rashes on the extensor surfaces of limbs. 
After one day, bullous eruptions of the oral mucosa were 
marked and maculopapular rashes were present all over 
the body, except on the face. Purulent conjunctivitis 
developed bilaterally, although bullous eruptions were 
absent. The condition was treated by stopping car-
bamazepine and adding oral prednisolone (120 mg/day in 
tapering dosage) and parenteral Gentamicin 80 mg twice 
daily. Within a week, severe ulceration of the oral mucosa 
was seen. Hemorrhagic crusting and a grayish white 
membrane were visible on the lips and inner oral cavity. 
The skin lesions showed typical "target lesions" with 
necrotized central area and yellowish red swollen margins, 
spread all over the body, except the face. No bullous 
lesions over the skin were seen. After 4 weeks, the mucosal 
and skin lesions started subsiding; the eyes were the first 
to clear and no sequelae were evident. 
Laboratory investigations including complete blood 
counts, hepatic and pancreatic enzymes were within nor-
mal limits. Urinalysisdid not show any significant finding. 
DISCUSSION 
After millions of prescriptions of carbamazepine, 
mostly as an antiepileptic, there are only a few reported 
cases of Stevens-Johnson syndrome due to this drug. It is 
of interest to observe this condition in a schizophrenic 
patient treated with carbamazepine, because it is very 
infrequently used for this purpose. To the best of our 
knowledge, there is only one reported case of Stevens-
Johnson syndrome where the drug was given for 
psychiatric illness (Fawcett, 1987). The diagnosis was 
consistent with the clinical description given in standard 
dermatology text books. In the absence of any other sys-
temic or local infection or exposure to another drug in the 
recent past except pimozide, and with the fact that condi-
tion improved with the discontinuation of carbamazepine, 
suggests that the condition was perhaps caused by car-
bamazepine. 
The studies on carbamazepine in psychiatry done so 
far, have mostly reported on it's efficacy in different 
mental disorders; it's adverse effects in psychiatric 
patients have found little attention. The belief that adverse 
effects in psychiatric patients are as frequent as in 
neurological patients is not true. In a study by Elphick 
(1988), the incidence of skin rashes in psychiatric patients 
(12%-15%) was much higher than neurological patients 
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(upto 5%), while they were on similar doses of car-
bamazepine. Similarly, the observation about the rarity of 
Stevens-Johnson syndrome in neurological patients while 
on carbamazepine treatment may not prove true for the 
psychiatric population. The occurrence of life threatening 
conditions like one described above, whatever be it's 
frequency, is a reminder that carbamazepine treatment 
carries potential risk. In clinical conditions like 
schizophrenia, the marginal benefits of carbamazepine are 
to be weighed against disastrous side effects before start-
ing the therapy. 
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